Arcus Biosciences Quick Ratio 2017-2022 | RCUS
Historical quick ratio values for Arcus Biosciences (RCUS) over the last 10 years.
Arcus Biosciences Quick Ratio Historical Data |
Date |
Current Assets - Inventory |
Current Liabilities |
Quick Ratio |
2022-12-31 |
$0.00B |
$0.19B |
0.00 |
2022-09-30 |
$0.00B |
$0.18B |
0.00 |
2022-06-30 |
$0.00B |
$0.16B |
0.00 |
2022-03-31 |
$0.00B |
$0.16B |
0.00 |
2021-12-31 |
$0.00B |
$0.17B |
0.00 |
2021-09-30 |
$0.00B |
$0.14B |
0.00 |
2021-06-30 |
$0.00B |
$0.13B |
0.00 |
2021-03-31 |
$0.00B |
$0.13B |
0.00 |
2020-12-31 |
$0.00B |
$0.12B |
0.00 |
2020-09-30 |
$0.00B |
$0.16B |
0.00 |
2020-06-30 |
$0.00B |
$0.04B |
0.00 |
2020-03-31 |
$0.00B |
$0.02B |
0.00 |
2019-12-31 |
$0.00B |
$0.02B |
0.00 |
2019-09-30 |
$0.00B |
$0.02B |
0.00 |
2019-06-30 |
$0.00B |
$0.03B |
0.00 |
2019-03-31 |
$0.00B |
$0.02B |
0.00 |
2018-12-31 |
$0.00B |
$0.02B |
0.00 |
2018-09-30 |
$0.00B |
$0.02B |
0.00 |
2018-06-30 |
$0.00B |
$0.02B |
0.00 |
2018-03-31 |
$0.00B |
$0.01B |
0.00 |
2017-12-31 |
$0.00B |
$0.01B |
0.00 |
2017-09-30 |
$0.00B |
|
0.00 |
2017-06-30 |
$0.00B |
|
0.00 |
2017-03-31 |
$0.00B |
|
0.00 |
2016-12-31 |
$0.00B |
|
0.00 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$1.194B |
$0.112B |
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
|